{"ATC Code":"R - Respiratory system","Abbreviation":"","Aliases":["Triprolidin","Tripolidina","Triprolidinum","Triprolidina","CCRIS 7212","trans-1-(2-Pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene","NCI-C61450","trans-1-(4-Methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene","trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine","(E)-2-(1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)pyridine"],"Biological Half-Life":"4 to 6 hours.","CAS":"486-12-4","ChEBI":"CHEBI:84116","ChEMBL":"CHEMBL855","ChemicalClasses":["phenidate"],"Chirality":"achiral","Classes":null,"Color/Form":"Crystals from light petroleum","Dosing Info":[],"Drug Classes":"Breast Feeding; Lactation; Antihistamines","Drug Indication":"For the symptomatic relief of seasonal or perennial allergic rhinitis or nonallergic rhinitis; allergic conjunctivitis; and mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Also used in combination with other agents for the symptomatic relief of symptoms associated with the common cold.","Drug Warnings":"Use is not recommended in newborn or premature infants because this age group has an increased susceptibility to anticholinergic side effects, such as central nervous system excitation, and an increased tendency toward convulsions. A paradoxical reaction characterized by hyperexcitability may occur in children taking antihistamines. /Antihistamines/","DrugClasses":[],"EINECS":"207-627-0","European Community (EC) Number":"207-627-0","FullSalts":["Triprolidine hydrochloride"],"HMDB ID":"HMDB0014571","HeavyAtomCount":21,"Human Drugs":"Breast Feeding; Lactation; Antihistamines","IUPACName":"2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine","InChI":"InChI=1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+","InChIKey":"CBEQULMOCCWAQT-WOJGMQOQSA-N","MeSH Pharmacological Classification":"Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)","Melting Point":"59-61 °C","MolecularFormula":"C\u003csub\u003e19\u003c/sub\u003eH\u003csub\u003e22\u003c/sub\u003eN\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"278.4 g/mol","Pharmacodynamics":"In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Triprolidine, is a histamine H1 antagonist that competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies. Triprolidine has anticholinergic and sedative effects.","Physical Description":"Solid","PrevSalts":["hydrochloride"],"PubChemId":5282443,"Record Description":["Triprolidine is an N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders. It has a role as a H1-receptor antagonist. It is a N-alkylpyrrolidine, a member of pyridines and an olefinic compound. It is a conjugate base of a triprolidine(1+).","First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.","Triprolidine is a first generation antihistamine that is used for symptoms of allergic rhinitis and the common cold and as a short acting sedative. Triprolidine has not been linked to instances of clinically apparent acute liver injury.","TRIPROLIDINE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 5 approved indications.","Histamine H1 antagonist used in allergic rhinitis; ASTHMA; and URTICARIA. It is a component of COUGH and COLD medicines. It may cause drowsiness.","See also: Triprolidine Hydrochloride (has salt form) ... View More ...","Triprolidine is an N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders. It has a role as a H1-receptor antagonist. It is a N-alkylpyrrolidine, a member of pyridines and an olefinic compound. It is a conjugate base of a triprolidine(1+).","LiverTox|Respiratory|Allergy symptoms|Antihistamine"],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Triprolidine","Name":"Triprolidine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q417654","Name":"Triprolidine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00427","Name":"Triprolidine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/5282443","Name":"Triprolidine","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL855","Name":"Triprolidine","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:84116","Name":"Triprolidine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=486-12-4","Name":"Triprolidine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014571","Name":"Triprolidine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D08648","Name":"Triprolidine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/2L8T9S52QM","Name":"Triprolidine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID3023718","Name":"Triprolidine","Sub":false}]}],"SMILES":"CC1=CC=C(C=C1)/C(=C\\CN2CCCC2)/C3=CC=CC=N3","Salts":["hydrochloride"],"SaltsAcidCount":[1],"SaltsAmineCount":[1],"SaltsUNII":["YAN7R5L890"],"Solubility":"5.37e-02 g/L","StoreUNII":["2L8T9S52QM"],"StructureBase64":"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","Therapeutic Uses":"Anti-Allergic Agents; Histamine H1 Antagonists","Title":"Triprolidine","UNII":"2L8T9S52QM","Wikidata":"Q417654","Wikipedia":"Triprolidine","XLogP":3.9}